Resistance Mechanisms to Anti-PD Cancer Immunotherapy.

Vesely, Matthew D; Zhang, Tianxiang; Chen, Lieping

Vesely, Matthew D; Zhang, Tianxiang; Chen, Lieping.

Afiliação

Vesely MD; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA; email: lieping.chen@yale.edu.
Zhang T; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Chen L; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA; email: lieping.chen@yale.edu.

Annu Rev Immunol ; 40: 45-74, 2022 04 26.

Article em En | MEDLINE | ID: mdl-35471840

Assuntos

Neoplasias; Receptor de Morte Celular Programada 1; Animais; Antígeno B7-H1; Humanos; Imunoterapia; Neoplasias/tratamento farmacológico; Neoplasias/metabolismo; Linfócitos T; Microambiente Tumoral

Palavras-chave

PD-1/B7-H1; anti-PD-1/PD-L1 therapy; immunotherapy resistance; normalization cancer immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Neoplasias Limite: Animals / Humans Idioma: En Revista: Annu Rev Immunol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google